This Funding Opportunity Announcement (FOA) supports Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that will develop and/or validate devices or electronic systems that can: 1) monitor biologically- or behaviorally-based processes applicable to mind and body interventions or 2) be used to assist in optimizing the practice or increasing the efficacy of mind and body interventions. The applications should: 1) lead to the development of new technologies, 2) adapt existing innovative technologies, devices and/or electronic systems, 3) repurpose existing devices and electronic systems, or 4) conduct testing of single or combined components of an integrated, long term, automated, wearable monitoring, stimulation device or electronic system in order to monitor or enhance the mechanistic processes or functional outcomes of mind and body interventions. For the purposes of this FOA, mind and body interventions are defined as non-pharmacological approaches that include mind/brain focused interventions (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), or combined mind and body meditative movement approaches (e.g., yoga, tai-chi, qigong).
This notice announces the opportunity to apply for funding under the Ryan White HIV/AIDS (RWHAP) Program Part A Planning Council and Planning Body Technical Assistance (TA) Cooperative Agreement. The goal of this cooperative agreement is to provide comprehensive technical assistance to RWHAP Part A Planning Councils and Planning Bodies (Planning Councils/Bodies) to enable them to enhance their abilities to successfully meet legislative responsibilities. In an effort to meet goals and legislative responsibilities, the Health Resources and Services Administration (HRSA) will engage an organization with national reach to provide Planning Council- and transitional grant area (TGA) Planning Body-related technical assistance to recipients, jurisdictional leadership, and Planning Councils/Bodies support staff. Comprehensive site visits conducted by the HIV/AIDS Bureau (HAB) Division of Metropolitan HIV/AIDS Programs (DMHAP) for each of the 52 RWHAP Part A jurisdictions have identified a critical need for an ongoing, comprehensive technical assistance mechanism for Part A Planning Councils/Bodies. This technical assistance and support will enable them to enhance their abilities to successfully meet legislative requirements, strengthen their role in providing essential engagement of people with HIV, and increase the involvement of prevention and care and treatment providers in the RWHAP Part A planning process. The recipient of this cooperative agreement will offer a full range of technical assistance delivered through both in-person and virtual methods, including but not limited to creating and updating resource guidance tools.
This notice announces the opportunity to apply for funding under the fiscal year (FY) 2019 RWHAP Integrated HIV/AIDS Planning and Resource Allocation Cooperative Agreement. The purpose of this cooperative agreement is to provide tools, training and technical assistance to RWHAP Parts A and B recipients and their planning bodies. RWHAP Parts A and B recipients and planning bodies submit Integrated Plans/ Statewide Coordinated Statements of Need (SCSN) to HRSA and the Centers for Disease Control and Prevention (CDC) in response to legislative and programmatic requirements. Recipients and planning bodies must use Integrated Plans/SCSN to better inform and coordinate HIV prevention and care program planning, priority setting, resource allocation, and continuous quality improvement efforts to meet the HIV service delivery needs within their jurisdictions. The primary goals of this cooperative agreement are to ensure that RWHAP Part A and B recipients and planning bodies: 1) develop an Integrated Plan/SCSN for their jurisdiction that reflects the community's vision and values regarding how best to develop a comprehensive and coordinated system of HIV prevention and care that can address unmet need among people living with HIV (PLWH); and 2) use the Integrated Plan/SCSN as a guide to end the HIV epidemic within their jurisdiction.
This funding opportunity announcement (FOA) encourages exploratory /developmental research grant applications (R21) to investigate the fundamental science of mind and body approaches, including mind/brain-focused practices (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), meditative exercise (e.g., yoga, tai chi, qi gong), art and music therapies, or integrative approaches combining several components. Studies of pharmacologic approaches exclusively are not included in the scope of this FOA.
The purpose of this FOA is to provide one year of support for planning activities necessary for initiating a Phase III clinical trial designed to treat patients with Lewy Body Dementias (LBD), which include Dementia with Lewy Bodies and Parkinson's Disease Dementia. Such activities may include identifying trial sites/collaborators, designing trial protocols and procedures, and addressing regulatory approvals.
Malawi faces chronic shortages, skill mix imbalances, and uneven geographical distribution of professionally qualified health workers such as medical doctors, clinical officers, nurse midwives, and allied health professionals. The purpose of this Funding Opportunity Announcement (FOA) is to provide technical assistance (TA) to the Government of Malawi in support of the national HIV response through the secondment of technical assistance (Technical assistants recruited and posted to requesting institutions to continue support to the HIV program (TA positions for Care and Treatment, Logistics and Supply Chain, Monitoring and Evaluation)) to the Ministry of Health (MOH) and other organizations, implementation of a fellowship program to develop technical and leadership capacity for HIV program management, provision of technical assistance to regulatory bodies (Medical Council of Malawi, Nurses and Midwives Council of Malawi and Pharmacy Medicines and Poisons Board), and improvement of the quality of in-service and pre-service education for critical health worker cadres in collaboration with Ministry of Health and training institutions under the University of Malawi and the Christian Health Association of Malawi (CHAM). Key outcomes of this program include the development and dissemination of technical guidelines, teaching materials, and tools for curricula strengthening. Teaching sites will be appropriately equipped and staffed. Capacity gaps in national programs will be addressed through the recruitment and deployment of technical assistants & fellows. In addition, the roles of regulatory bodies in education will be strengthened through the provision of technical assistance
The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This will lower the risk of adopting the target in translational projects to develop small molecules, biologics, natural substances, or devices that interact with this target for new pain treatments. Translational research to develop new medical devices are not the focus of this FOA. Basic science studies of pain and related systems in the body are responsive to this FOA and are encouraged in the context of novel pain therapeutic target discovery. This FOA is not specific for any one or group of pain conditions. Projects to identify novel targets for acute pain, chronic pain, migraine, other headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, sickle-cell pain, post stroke pain, etc. will be considered. Projects to identify novel targets for a combination of chronic overlapping pain conditions or for specific pathological conditions will be considered. Projects that seek to identify novel targets in specific populations such as women, children, older adults or other underrepresented groups will also be responsive to this FOA.
NineSigma, representing a major global manufacturer of laboratory testing equipment/reagents, seeks joint research partners for providing evidence on association between heavy metals present in trace amounts in the body and the development of dementia / neurodevelopmental syndromes.
Heavy metals present in the environment, especially mercury and lead, are ingested daily through food, etc. and accumulated in the body. Although it has been suggested that excessive accumulation may cause damage to the cardiovascular and cerebral nervous systems, the mechanism of disease onset has not been elucidated.
This funding opportunity announcement (FOA) encourages innovative research to develop, characterize, and improve animal models, biological materials, and novel technologies to better understand human health and disease. This FOA also seeks projects aimed at improving the diagnosis and control of diseases that interfere with animal use for biomedical research. The proposed project must have broad application to multiple NIH Institutes or Centers (ICs) to align with the Office of Research Infrastructure Programs (ORIP) trans-NIH mission. The proposed studies must explore multiple body systems or evaluate diseases that impact multiple body systems. Applications that develop models focused on a specific disease or area of research, or only propose studies primarily relevant to a single NIH IC will be considered not responsive to this FOA and will not be accepted.
A growing body of evidence demonstrates that good adherence to recommended medications can yield better clinical outcomes and reduce downstream medical spending for patients with chronic conditions. However, many people do not take their medications as prescribed. Closing the adherence gap is important for improving the quality of health care, encouraging better chronic care management, and promoting better outcomes. Our goal is to support research that will advance knowledge of innovative and effective approaches to improve medication adherence. Relevant research goals may include development or evaluation of policies, interventions, or tools that have potential to improve medication adherence.
A growing body of evidence demonstrates that good adherence to recommended medications can yield better clinical outcomes and reduce downstream medical spending for patients with chronic conditions. However, many people do not take their medications as prescribed. Closing the adherence gap is important for improving the quality of health care, encouraging better chronic care management, and promoting better outcomes. Our goal is to support research that will advance knowledge of innovative and effective approaches to improve medication adherence. Relevant research goals may include development or evaluation of policies, interventions, or tools that have potential to improve medication adherence.
This FOA invites applications that will systematically and comprehensively characterize alpha-synuclein and amyloid-beta subspecies present in human Lewy Body Dementia (LBD) post-mortem brain tissue, identify toxic subspecies and potential mechanisms of toxicity, and characterize any interactions between the proteins that may contribute to increased toxicity and/or explain selective vulnerabilities of cells/circuits. Applications are required to include at least 3 hypothesis-driven projects that address these goals, an administrative core, and other cores as appropriate. Applicants will be expected to focus on the use of human tissues. All applications will be expected to include plans for developing a publicly-available library of fully characterized alpha-synuclein and amyloid-beta subspecies found in LBD.
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), the Division of Epidemiology, Statistics, and Prevention Research intends to solicit proposals to award a Research and Development (R&D) contract to an organization to conduct a prospective cohort study among pregnant women to evaluating dietary intake during pregnancy and postpartum, focusing on the associations of food reward responsivity and food reinforcement value with dietary intake, weight change, and body composition change during pregnancy and postpartum.
Human resources (HR) are an essential component of Zimbabwe's health system, and are therefore critical for an effective response to the HIV epidemic. Still recovering from the effects of the political crisis in the first decade of the 21st century, the country's health institutions are understaffed and the workforce overburdened. Efficient information systems can provide knowledge to equitably distribute scarce human resources. This includes both applications to manage information about the health sector workforce and means to electronically share information across systems. This funding opportunity announcement (FOA) will build on past and current CDC-supported activities at the Ministry of Health and Child Care (MOHCC) and the Health Professional Regulatory Bodies.
The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimers disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. There is particular interest in interventions that can be implemented in community settings by the affected individual, informal caregivers, or others in the community. Research to inform the development of such interventions is also of interest, as well as research examining underlying mechanisms and biomarkers associated with response to interventions. It is anticipated that the results of this research will help affected individuals maintain independence and quality of life, improve their ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs), and additionally help to reduce stress, burden, and other poor outcomes in their caregivers.
Eligibility criteria for TAT grants is as follows: (a) Entities eligible for grants must be private nonprofit organizations with tax exempt status, designated by the Internal Revenue Service. A nonprofit organization is defined as any corporation, trust, association, cooperative, or other organization that: (1) Is operated primarily for scientific, education, service, charitable, or similar purposes in the public interest. (2) Is not organized primarily for profit. (3) Uses its net proceeds to maintain, improve, and/or expand its operations. (b) Entities must be legally established and located within a state as defined in 1775.2. (c) Organizations must be incorporated by December 31 of the year the application period occurs to be eligible for funds. (d) Private businesses, Federal agencies, public bodies, and individuals are ineligible for these grants. (e) Applicants must also have the proven ability, background, experience (as evidenced by the organization satisfactory completion of project(s)similar to those proposed), legal authority, and actual capacity to provide technical assistance and/or training on a regional basis to associations as provided in 1775.33. To meet the requirement of actual capacity, an applicant must either: (1) Have the necessary resources to provide technical assistance and/or training to associations in rural areas through its staff, or (2) Be assisted by an affiliate or member organization which has such background and experience and which agrees, in writing, that it will provide the assistance, or (3) Contract with a nonaffiliated organization for not more than 49 percent of the grant to provide the proposed assistance.
The purpose of this FOA is to test a model of quality clinical care addressing childhood obesity for U.S. low-income children, especially those enrolled in or eligible for health care coverage under the Children’s Health Insurance Program (CHIP) or Medicaid. Specifically, the purpose of this FOA is to implement and test the ability of a model of clinical childhood obesity management along with a EHR-referral-based, family-centered pediatric weight management program, to reduce body mass index (BMI) in children with obesity, or overweight with risks (including, e.g., medical and behavioral risks, and family history).
This FOA is intended to encourage exploratory studies to : (1) increase our understanding of how music affects the brain, body, and behavior and (2) use that knowledge to develop evidence-based music interventions to enhance health or treat specific diseases and disorders. Proposed R21 projects can investigate how music is processed by or modifies the brain, or how it affects specific biological functions during childhood development and learning, adulthood, and aging. Projects can also include preliminary interventions that provide a basis for therapeutic interventions. When appropriate, collaborations among basic researchers, technology developers, music intervention experts, or other clinical researchers are highly encouraged.
This broad spectrum FOA is intended to: (1) increase our understanding of how music affects the brain, body, and behavior and (2) use that knowledge to develop evidence-based music interventions to enhance health or treat specific diseases and disorders. Proposed R01 projects can investigate how music is processed by or modifies the brain, or how it affects specific biological functions during childhood development and learning, adulthood, and aging. Projects can also include preliminary interventions that provide a basis for therapeutic interventions. When appropriate, collaborations among basic researchers, technology developers, music intervention experts, or other clinical researchers are highly encouraged.
The purpose of this FOA is to support the establishment of center(s) that will use cutting edge technologies to perform omics analyses (e.g. metabolomic, lipidomic, proteomic, extracellular RNA) of body fluids collected by the Acute to Chronic Pain Signatures (A2CPS) consortium. The omics data generated, in concert with other patient assessments, will be used to identify biosignatures predictive of susceptibility or resilience to the development of chronic pain.
The purpose of this Funding Opportunity Announcement (FOA) is to support a national network of research centers for development of effective and comprehensive medical countermeasures applicable to all subsets of the civilian population in the event of radiological or nuclear emergencies. Applications are sought that propose multidisciplinary basic and translational research to support the development of new medical products that will assess, diagnose, mitigate and/or treat the short-, delayed- and long-term consequences of radiation exposure during and following a radiation public health emergency (e.g. a radiological/nuclear terrorist incident or accident). The goals of this FOA are to: 1) develop new techniques and devices to measure radiation exposure in the human body; 2) follow biomarkers of tissue damage and recovery; and 3) further develop existing (e.g. products in clinical use) as well as novel therapies to minimize tissue damage, hasten tissue recovery, restore normal physiological function, and improve survival.